A Randomized, Double-blind, Double-dummy, Parallel-group, Multicenter Study to Demonstrate Improvement in Symptoms of Constipation in Subjects With Moderate to Severe Non-malignant Pain Taking Oxycodone Equivalent of ≥10 mg/Day and ≤50 mg/Day as Oxycodone/Naloxone Prolonged-release (OXN) Compared to Subjects Taking Oxycodone Prolonged-release (OXY) Tablets Alone.
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Oxycodone/naloxone (Primary) ; Oxycodone
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Sponsors Mundipharma International
- 03 Feb 2020 Primary endpoint (Bowel function index(BFI) 12 Weeks) has been met published in the Advances in Therapy
- 03 Feb 2020 Results published in the Advances in Therapy
- 10 Nov 2017 Status changed from recruiting to completed.